Page last updated: 2024-09-05

lapatinib and bafilomycin a

lapatinib has been researched along with bafilomycin a in 1 studies

Compound Research Comparison

Studies (lapatinib)	Trials (lapatinib)	Recent Studies (post-2010) (lapatinib)	Studies (bafilomycin a)	Trials (bafilomycin a)	Recent Studies (post-2010) (bafilomycin a)
1,919	305	1,442	312	0	117

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Komurov, K; Moss, TJ; Muller, M; Nagrath, D; Ram, PT; Seviour, EG; Tseng, JT; Yang, L	1

Other Studies

1 other study(ies) available for lapatinib and bafilomycin a

Article	Year
The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Molecular systems biology, 2012, Volume: 8 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Profiling; Genomics; Glucose; Humans; Hypoglycemic Agents; Lapatinib; Macrolides; Metformin; Models, Biological; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Signal Transduction	2012

Article

Year

The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.

Molecular systems biology, 2012, Volume: 8

Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression Profiling; Genomics; Glucose; Humans; Hypoglycemic Agents; Lapatinib; Macrolides; Metformin; Models, Biological; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Signal Transduction

2012